Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.34 |
| ▸ | KIF11 | P52732 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.32 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.32 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.32 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540945 | 0.79 | NOTUM (0.46) | NOTUMALDH1A1TSHR | |
| SCHEMBL2753545 | 0.77 | NOTUM (0.37) | NOTUM | |
| SCHEMBL5535953 | 0.75 | ELANE (0.38) | TDP1NOTUMALDH1A1TSHRMGLL | |
| SCHEMBL2751112 | 0.75 | ALDH1A1 (0.44) | TDP1NOTUMALDH1A1PKMCA2 | |
| SCHEMBL2749018 | 0.75 | ALDH1A1 (0.40) | TDP1ALDH1A1PKMTSHRCA2 | |
| SCHEMBL2238653 | 0.73 | ALDH1A1 (0.52) | TDP1KIF11ALDH1A1PKMTSHR | |
| SCHEMBL28682190 | 0.68 | TDP1 (0.41) | TDP1NOTUMKIF11ALDH1A1TSHR | |
| SCHEMBL6685857 | 0.68 | TDP1 (0.53) | TDP1ALDH1A1CA2 | |
| SCHEMBL2753214 | 0.65 | — | — | |
| SCHEMBL2752355 | 0.65 | NOTUM (0.41) | NOTUMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-101124216-A | Heterocyclic MCHr1 antagonists and their use in therapy | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | CN | disclosed |
| CN-101076332-A | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC THERAPEUTICS INC (US) | 2007-11-21 | — | — | CN | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20070185079-A1 | Therapeutic agents I | ASTRAZENECA AB (SE) | 2007-08-09 | — | — | US | disclosed |
| EP-1706384-A1 | THERAPEUTIC AGENTS I | AstraZeneca AB (SE) | 2006-10-04 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1613626-A1 | CYCLIC BENZIMIDAZOLES | ALTANA Pharma AG (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005066132-A1 | THERAPEUTIC AGENTS I | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004087701-A1 | CYCLIC BENZIMIDAZOLES | ALTANA PHARMA AG (DE) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | TDP1 4666/4885NOTUM 3827/4885KIF11 3946/4885 |
| US-20070185079-A1 | Therapeutic agents I | HTT, GRIN2A, GRIN1 | TDP1 2220/4885NOTUM 2106/4885KIF11 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.